Cargando…

Dopamine in plasma – a biomarker for myofascial TMD pain?

BACKGROUND: Dopaminergic pathways could be involved in the pathophysiology of myofascial temporomandibular disorders (M-TMD). This study investigated plasma levels of dopamine and serotonin (5-HT) in patients with M-TMD and in healthy subjects. METHODS: Fifteen patients with M-TMD and 15 age- and se...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, Andreas, Stensson, Niclas, Ghafouri, Bijar, Gerdle, Björn, List, Thomas, Svensson, Peter, Ernberg, Malin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936983/
https://www.ncbi.nlm.nih.gov/pubmed/27386870
http://dx.doi.org/10.1186/s10194-016-0656-3
_version_ 1782441625811681280
author Dawson, Andreas
Stensson, Niclas
Ghafouri, Bijar
Gerdle, Björn
List, Thomas
Svensson, Peter
Ernberg, Malin
author_facet Dawson, Andreas
Stensson, Niclas
Ghafouri, Bijar
Gerdle, Björn
List, Thomas
Svensson, Peter
Ernberg, Malin
author_sort Dawson, Andreas
collection PubMed
description BACKGROUND: Dopaminergic pathways could be involved in the pathophysiology of myofascial temporomandibular disorders (M-TMD). This study investigated plasma levels of dopamine and serotonin (5-HT) in patients with M-TMD and in healthy subjects. METHODS: Fifteen patients with M-TMD and 15 age- and sex-matched healthy subjects participated. The patients had received an M-TMD diagnosis according to the Research Diagnostic Criteria for TMD. Perceived mental stress, pain intensity (0–100-mm visual analogue scale), and pressure pain thresholds (PPT, kPa) over the masseter muscles were assessed; a venous blood sample was taken. RESULTS: Dopamine in plasma differed significantly between patients with M-TMD (4.98 ± 2.55 nM) and healthy controls (2.73 ± 1.24 nM; P < 0.01). No significant difference in plasma 5-HT was observed between the groups (P = 0.75). Patients reported significantly higher pain intensities (P < 0.001) and had lower PPTs (P < 0.01) compared with the healthy controls. Importantly, dopamine in plasma correlated significantly with present pain intensity (r = 0.53, n = 14, P < 0.05) and perceived mental stress (r = 0.34, n = 28, P < 0.05). CONCLUSIONS: The results suggest that peripheral dopamine might be involved in modulating peripheral pain. This finding, in addition to reports in other studies, suggests that dopaminergic pathways could be implicated in the pathophysiology of M-TMD but also in other chronic pain conditions. More research is warranted to elucidate the role of peripheral dopamine in the pathophysiology of chronic pain.
format Online
Article
Text
id pubmed-4936983
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-49369832016-07-08 Dopamine in plasma – a biomarker for myofascial TMD pain? Dawson, Andreas Stensson, Niclas Ghafouri, Bijar Gerdle, Björn List, Thomas Svensson, Peter Ernberg, Malin J Headache Pain Research Article BACKGROUND: Dopaminergic pathways could be involved in the pathophysiology of myofascial temporomandibular disorders (M-TMD). This study investigated plasma levels of dopamine and serotonin (5-HT) in patients with M-TMD and in healthy subjects. METHODS: Fifteen patients with M-TMD and 15 age- and sex-matched healthy subjects participated. The patients had received an M-TMD diagnosis according to the Research Diagnostic Criteria for TMD. Perceived mental stress, pain intensity (0–100-mm visual analogue scale), and pressure pain thresholds (PPT, kPa) over the masseter muscles were assessed; a venous blood sample was taken. RESULTS: Dopamine in plasma differed significantly between patients with M-TMD (4.98 ± 2.55 nM) and healthy controls (2.73 ± 1.24 nM; P < 0.01). No significant difference in plasma 5-HT was observed between the groups (P = 0.75). Patients reported significantly higher pain intensities (P < 0.001) and had lower PPTs (P < 0.01) compared with the healthy controls. Importantly, dopamine in plasma correlated significantly with present pain intensity (r = 0.53, n = 14, P < 0.05) and perceived mental stress (r = 0.34, n = 28, P < 0.05). CONCLUSIONS: The results suggest that peripheral dopamine might be involved in modulating peripheral pain. This finding, in addition to reports in other studies, suggests that dopaminergic pathways could be implicated in the pathophysiology of M-TMD but also in other chronic pain conditions. More research is warranted to elucidate the role of peripheral dopamine in the pathophysiology of chronic pain. Springer Milan 2016-07-07 /pmc/articles/PMC4936983/ /pubmed/27386870 http://dx.doi.org/10.1186/s10194-016-0656-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Dawson, Andreas
Stensson, Niclas
Ghafouri, Bijar
Gerdle, Björn
List, Thomas
Svensson, Peter
Ernberg, Malin
Dopamine in plasma – a biomarker for myofascial TMD pain?
title Dopamine in plasma – a biomarker for myofascial TMD pain?
title_full Dopamine in plasma – a biomarker for myofascial TMD pain?
title_fullStr Dopamine in plasma – a biomarker for myofascial TMD pain?
title_full_unstemmed Dopamine in plasma – a biomarker for myofascial TMD pain?
title_short Dopamine in plasma – a biomarker for myofascial TMD pain?
title_sort dopamine in plasma – a biomarker for myofascial tmd pain?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936983/
https://www.ncbi.nlm.nih.gov/pubmed/27386870
http://dx.doi.org/10.1186/s10194-016-0656-3
work_keys_str_mv AT dawsonandreas dopamineinplasmaabiomarkerformyofascialtmdpain
AT stenssonniclas dopamineinplasmaabiomarkerformyofascialtmdpain
AT ghafouribijar dopamineinplasmaabiomarkerformyofascialtmdpain
AT gerdlebjorn dopamineinplasmaabiomarkerformyofascialtmdpain
AT listthomas dopamineinplasmaabiomarkerformyofascialtmdpain
AT svenssonpeter dopamineinplasmaabiomarkerformyofascialtmdpain
AT ernbergmalin dopamineinplasmaabiomarkerformyofascialtmdpain